8-K: Kyverna Therapeutics Announces Business Update and Full Year 2024 Financial Results, Highlights Progress in Autoimmune Disease Therapies

Kyverna Therapeutics reports financial results for 2024 and provides a business update, highlighting progress in clinical trials for autoimmune diseases and a cash runway into 2027.

Summary

• Kyverna Therapeutics reported its business highlights and financial results for the full year 2024.
• The company is focused on developing cell therapies for autoimmune diseases.
• Kyverna's lead candidate, KYV-101, is being evaluated in clinical trials for stiff person syndrome, myasthenia gravis, and lupus nephritis.
• Kyverna has aligned with the FDA on a registrational Phase 2 design for its KYSA-8 trial in stiff person syndrome, with 70% of study participants enrolled.
• Topline data from the KYSA-8 trial is expected in the first half of 2026, with a BLA filing targeted for 2026.
• Interim data from the Phase 2 trial in myasthenia gravis is expected in the second half of 2025.
• Phase 1 data from the lupus nephritis trials is expected in the second half of 2025.
• Kyverna expects to file an investigational new drug application for KYV-102 in the second half of 2025.
• The company reported $286.0 million in cash, cash equivalents, and available-for-sale marketable securities as of December 31, 2024.
• This cash is expected to provide a runway into 2027.
• For the year ended December 31, 2024, the company reported a net loss of $127.5 million, or a net loss per common share of $3.33.
• Net cash used in operating activities was $114.3 million for the year ended December 31, 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting clinical progress and a strong cash position, but also acknowledges significant net losses. The sentiment is cautiously optimistic.

Positives

• Kyverna has aligned with the FDA on a registrational Phase 2 design for its KYSA-8 trial in stiff person syndrome.
• The KYSA-8 trial has enrolled 70% of study participants.
• Kyverna has a strong cash position of $286.0 million, providing a cash runway into 2027.
• The company has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation from the FDA for its stiff person syndrome program.
• The company has received RMAT Designation and Fast Track Designation from the FDA as well as Orphan Drug Designation from both the FDA and European Medicines Agency for its myasthenia gravis program.
• The company has received Fast Track Designation from the FDA for its lupus nephritis program.
• Kyverna has strengthened its management team with several key appointments.

Negatives

• The company reported a net loss of $127.5 million for the year ended December 31, 2024.
• Net cash used in operating activities was $114.3 million for the year ended December 31, 2024.

Risks

• Uncertainties related to market conditions could impact Kyverna's plans.
• The FDA or other regulatory agencies may require additional trials or studies to support the BLA submission for KYV-101.
• The company's clinical trials may not be successful.
• The company may face challenges in manufacturing and commercializing its products.

Future Outlook

Kyverna anticipates key milestones including completing enrollment for the pivotal Phase 2 trial in SPS in mid-2025, reporting topline data from this trial in the first half of 2026, and submitting its first BLA in 2026. The company also expects to report interim Phase 2 data in myasthenia gravis and Phase 1 data in lupus nephritis in the second half of 2025, and file an IND application for KYV-102 in the second half of 2025.

Management Comments

• Kyvernas first year as a public company was a transformative one, as we demonstrated our leadership position in autoimmune CAR T, said Warner Biddle, Chief Executive Officer of Kyverna.
• We have treated the most CAR T patients in neuroinflammatory and rheumatologic diseases with our differentiated construct, and our clinical experience to date highlights the potential for profound clinical outcomes in autoimmune patients.
• Kyverna has entered 2025 and its next phase of growth with the right strategy and a strong team in place to advance late-stage development of KYV-101 in our three priority indications stiff person syndrome, myasthenia gravis and lupus nephritis each with a clear and rapid path to market.
• We are pleased with our progress in our lead indication, stiff person syndrome, following alignment with the FDA on our registrational trial, KYSA-8, which is an important milestone as we advance KYV-101 toward its first BLA filing in 2026.

Industry Context

Kyverna is operating in the competitive field of cell therapies for autoimmune diseases, where companies are striving to develop more effective and durable treatments. The company's focus on fully human CAR T-cell therapies and its progress in clinical trials position it as a key player in this space.

Comparison to Industry Standards

• Kyverna's approach to CAR T-cell therapy for autoimmune diseases is similar to that of companies like Cartesian Therapeutics and Cabaletta Bio, which are also developing CAR T therapies for autoimmune disorders.
• The company's focus on stiff person syndrome, myasthenia gravis, and lupus nephritis aligns with the industry's growing interest in targeting specific autoimmune diseases with tailored therapies.
• Kyverna's cash runway into 2027 is comparable to that of other clinical-stage biopharmaceutical companies, providing it with sufficient resources to advance its clinical programs.

Management Changes

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and strong cash position are positive for shareholders.
• Employees: The company's growth and strengthened management team are positive for employees.
• Patients: The company's development of new therapies for autoimmune diseases has the potential to improve the lives of patients.

Next Steps

• Complete pivotal Phase 2 enrollment for stiff person syndrome in mid-2025.
• Report topline pivotal Phase 2 data for stiff person syndrome in 1H 2026.
• File BLA for stiff person syndrome in 2026.
• Confirm registrational path with regulators for myasthenia gravis in 1H 2025.
• Report interim Phase 2 data for myasthenia gravis in 2H 2025.
• Report Phase 1 data for lupus nephritis in 2H 2025.
• File KYV-102 IND application in 2H 2025.

Key Dates

Keywords

KYV-101, KYV-102, autoimmune diseases, cell therapy, stiff person syndrome, myasthenia gravis, lupus nephritis, clinical trials, FDA, biopharmaceutical, CAR T-cell therapy